Current status of biomedical products for gene and cellular therapy of recessive dystrophic epidermolysis bullosa (part I)
- 25 April 2025
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (2)
Abstract
A detailed review of current products and innovative strategies of gene and cellular therapy, which are at different study phases, in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) is provided. The most promising in cellular RDEB therapy is application of allogenic mesenchymal stromal/stem cells that can be injected intradermally and intravenously. Genetically modified autologous dermal fibroblasts, which are injected intradermally along the wound edges also should be noted among the injection methods. Epidermal transplants, based on patient’s autologous keratinocytes, have been developed ex vivo on the basis of gene therapy methods. Products based on double-layer transplants, including both types of skin cells producing C7, have been developed as well. These are the most advanced technologies in pre-clinical and clinical studies, and the gene product in vivo, namely a local gene therapy on the basis of herpes simplex virus type 1 aimed at C7 protein restoration by delivering COL7A1, is the first method of gene therapy, that can already be used in a clinical setting for RDEB treatment. Products based on gene editing using nucleases are also being developed. The review discusses in detail the results of pre-clinical and clinical studies of above mentioned products.Keywords
This publication has 73 references indexed in Scilit:
- Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis BullosaDermatology and Therapy, 2021
- Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis BullosaJAMA, 2016
- Clinical-instrumental and morphological evaluation of the effect of autologous dermal fibroblasts administrationJournal of Tissue Engineering and Regenerative Medicine, 2014
- A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaJournal of the American Academy of Dermatology, 2013
- Type VII Collagen: The Anchoring Fibril Protein at Fault in Dystrophic Epidermolysis BullosaDermatologic Clinics, 2010
- Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006Journal of the American Academy of Dermatology, 2009
- Human skin stem cells and the ageing processExperimental Gerontology, 2008
- Progress in epidermolysis bullosa: Genetic classification and clinical implicationsAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2004
- Participation of bone marrow derived cells in cutaneous wound healingJournal of Cellular Physiology, 2003
- Effect of Growth Factors on Cell Proliferation and Epithelialization in Human SkinJournal of Surgical Research, 1995